Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

1.578 +0.058 (+3.79%)

Streaming Delayed Price Updated: 12:26 PM EST, Dec 24, 2025 Add to My Watchlist

Price and Volume

Volume	257,687
Open	1.520
Bid (Size)	1.550 (100)
Ask (Size)	1.590 (100)
Prev. Close	1.520
Today's Range	1.510 - 1.600
52wk Range	1.490 - 8.940
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

December 22, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

December 15, 2025

From Medicus Pharma Ltd

Via GlobeNewswire

Performance

YTD	-37.1%	-37.1%
1 Month	-20.3%	-20.3%
3 Month	-43.7%	-43.7%
6 Month	-35.6%	-35.6%
1 Year	-43.0%	-43.0%

More News

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

December 05, 2025

Via ACCESS Newswire

Let's take a look at the stocks that are in motion in today's session. ↗

December 04, 2025

Via Chartmill

Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch

December 04, 2025

Via AB Newswire

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

December 01, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

November 24, 2025

From Medicus Pharma Ltd.

Via GlobeNewswire

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 17, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 17, 2025

From Medicus Pharma

Via GlobeNewswire

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

November 14, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 13, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries

November 05, 2025

Via AB Newswire

Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)

October 30, 2025

Via AB Newswire

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

October 29, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

October 29, 2025

From Medicus Pharma

Via GlobeNewswire

4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)

October 23, 2025

Via AB Newswire

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

October 22, 2025

Via ACCESS Newswire

4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)

October 16, 2025

Via AB Newswire

Three Biotech Companies Redefining Value Creation Through Dual Strategies

October 14, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

October 13, 2025

Via ACCESS Newswire

Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology

October 10, 2025

Via AB Newswire

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

October 07, 2025

Via ACCESS Newswire

Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 Billion Cancer Market

October 02, 2025

Via AB Newswire

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

September 29, 2025

Via ACCESS Newswire

Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics

September 26, 2025

Via News Direct

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?

Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.

What exchange does Medicus Pharma Ltd. - Common Stock trade on?

Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?

The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market

What is the current price of Medicus Pharma Ltd. - Common Stock?

The current price of Medicus Pharma Ltd. - Common Stock is 1.578

When was Medicus Pharma Ltd. - Common Stock last traded?

The last trade of Medicus Pharma Ltd. - Common Stock was at 12/24/25 12:26 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.